# Maravai LifeSciences Holdings Inc. (MRVI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.32, market value $2.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Maravai LifeSciences Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 13.0×**. Each dollar of revenue is priced at 13.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.3×**. The shares trade at 5.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.3%** (5-yr avg 1.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -56.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -70.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -61.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -32.2%**. Return on all capital, debt included, is -32.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -10.0%**. Each dollar of assets produces -10.0% of profit.

## Growth
- **Revenue growth (1 yr): -28.3%** (3-yr -40.5%/yr, 5-yr -8.1%/yr). Revenue fell 28.3% over the last year, against -8.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 14.3%**. Earnings per share rose 14.3%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.37**. Debt is 1.37 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Altman Z-score: 3.79**. A Z-score of 3.79 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Maravai LifeSciences Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 210.2%** (YTD 125.2%, 3-mo 45.8%). The shares are up 210.2% over twelve months including dividends.
- **From 52-week high: -22.3%** (202.5% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.45** (volatility 69%). Beta of 1.45 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MRVI · Page: https://foliofundamentals.com/stocks/mrvi

Not investment advice.